Introduction
The neuroscience community has faced a formidable challenge in addressing the pathologic potential of misfolded proteins, an issue that underlies a spectrum of debilitating neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). A study led by researchers at Johns Hopkins University has unveiled significant insights into a novel protein quality control pathway implicated in these disorders. In their groundbreaking research, Lu Jiayin and colleagues identified the role of Lethal(3)malignant brain tumor-like protein 1 (L3MBTL1), providing a vital link to understanding ALS/FTD-associated proteotoxicity.
The Proteotoxicity Problem in ALS/FTD
In neurodegenerative diseases like ALS and FTD, the accumulation of misfolded proteins triggers proteotoxic stress, leading to cellular dysfunction and death. The proteins Cu/Zn superoxide dismutase (SOD1) and C9orf72 dipeptide repeat proteins are particularly implicated in ALS and FTD. The failure to mitigate this proteotoxicity through efficient protein quality control systems is a central theme in the relentless progression of these disorders.
L3MBTL1: A New Protagonist in Protein Quality Control
The findings published in *Nature Neuroscience* outline the role of L3MBTL1 as a regulator of the protein quality control mechanisms that are critical for neuronal health. Notably, the depletion of L3MBTL1 was found to confer protection against the toxicity of mutant SOD1 and C9orf72 proteins. L3MBTL1 operates through regulation of p53-dependent systems that are responsible for the degradation of misfolded proteins. This crucial function underscores the protein’s significance in the cellular stress response and potentially serves as a focal point for therapeutic intervention.
Moreover, the research emphasizes the association of L3MBTL1 with SET domain-containing protein 8 (SETD8), a p53-binding protein that further modulates the clearance of misfolded proteins. The stress responsive increase in SETD8 highlights an adaptive, yet potentially deleterious response to proteotoxicity.
Upregulation of L3MBTL1 and SETD8 in ALS/FTD Models
Importantly, the study has provided evidence that L3MBTL1 and SETD8 are upregulated in the central nervous systems of both mouse models of ALS and human ALS/FTD patients. This upregulation may represent a maladaptive response to the overwhelming presence of misfolded proteins characteristic of these diseases. This discovery presents an opportunity to develop targeted therapies that could modulate these proteins and ameliorate disease progression.
Conservation Across Species: Implications for Broad Therapy
The significance of L3MBTL1 extends across species, with its function conserved from the simple organism *Caenorhabditis elegans* to complex mammalian neurons. This evolutionary conservation suggests that pathways involving L3MBTL1 have been pivotal in maintaining cellular integrity against protein misfolding, presenting a broad target for therapeutic interventions that could cater to a multitude of species, including humans.
Conclusion and Future Directions
This pioneering study by Jiayin et al. sets a precedent for exploring the intricate network of proteins involved in maintaining proteostasis and opens a new avenue for therapeutic development. The elucidation of the L3MBTL1-dependent quality control pathway provides a beacon of hope, not only for understanding the molecular intricacies of ALS and FTD but also for devising innovative strategies to counteract the ravages of protein misfolding in neurodegenerative diseases.
DOI and References
DOI: 10.1038/s41593-019-0384-5
References
1. Balch WE, Morimoto RI, Dillin A & Kelly JW. Adapting Proteostasis for Disease Intervention. Science. 2008;319(916-919). doi: 10.1126/science.1141448.
2. Bosco DA, et al. Wild-type and mutant SOD1 share an aberrant conformation and a common pathogenic pathway in ALS. Nat Neurosci. 2010;13(1396-1403). doi: 10.1038/nn.2660.
3. DeJesus-Hernandez M, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72(245-256). doi: 10.1016/j.neuron.2011.09.011.
4. Periz G, et al. Regulation of Protein Quality Control by UBE4B and LSD1 through p53-Mediated Transcription. PLoS Biol. 2015;13(e1002114). doi: 10.1371/journal.pbio.1002114.
5. Wang J, et al. An ALS-linked mutant SOD1 produces a locomotor defect associated with aggregation and synaptic dysfunction when expressed in neurons of Caenorhabditis elegans. PLoS Genet. 2009;5(e1000350). doi: 10.1371/journal.pgen.1000350.
Keywords
1. L3MBTL1 in neurodegeneration
2. Protein quality control ALS
3. SETD8 protein regulation
4. Proteotoxic stress response
5. Therapeutic targets for FTD